AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05647096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: 100ml NucleoCapture selective DNA adsorber
Study NCT04765111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04765111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05956821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIACI of cetuximab and bevacizumab
Description: Subjects will receive monthly dosing of bevacizumab (15 mg/kg) and cetuximab (200mg/m2)
Study NCT05271162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg q.d; p.o
Study NCT05271162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tabl q.d; p.o
Study NCT04774406 — intervention group
Intervention type: DRUG
Intervention: olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
Description: All patients treated at least with 1 PARPi (alone or in combination)
Study NCT06500949 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Pulmonary Branch Block
Description: Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of 0.375% ropivacaine was administered in close proximity to the targeted vagal branch.
Study NCT06500949 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vagus Nerve Pulmonary Branch Injection
Description: Following thoracotomy, the thoracic surgeon, under direct thoracoscopic guidance, used forceps to elevate the apex of the lung, thus exposing the main trunk of the pulmonary branches of the vagus nerve. The injection needle was then advanced from a lateral-to-medial direction, and 2.5 ml of normal saline was administered in close proximity to the targeted vagal branch.
Study NCT05338983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration
Study NCT05338983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: 20% Benzocaine gel will be applied on the area of infiltration
Study NCT05338983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avent baby bottle warmer
Description: Warming device
Study NCT05338983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: 0.1ml of 8.4% of sodium bicarbonate will be removed from the 50ml vial by one ml insulin syringe , directly injected into the local anesthetic cartridge and will be shacked 5 times to mix the solution.
Study NCT05338983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy device
Description: Bee-shaped apparatus consisting of two parts: the main vibrating body of a bee and detachable ice wings.~External application of Buzzy device during administration of dental anesthetic.
Study NCT05338983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
Study NCT05338983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine Hydrochloride
Description: Mepivacaine HCL 2% with Epinephrine 1:100,000 Local Anesthetic. Local Dental anesthetic infiltration
Study NCT05310721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating
Description: Participants will eat ad libitum within an 8-hour early eating window starting not later than 10am. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Study NCT05310721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late time-restricted eating
Description: Participants will eat ad libitum within an 8-hour late eating window starting not earlier than 1pm. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Study NCT05310721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-selected time-restricted eating
Description: Participants will self-selected an 8-hour eating window to eat ad libitum. No calorie-containing food or beverage intake will be allowed outside the 8-hour eating window. Participants will also receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion
Study NCT04633343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small volume breath and fast breathing rate for 5 minutes
Description: Small volume breath and fast breathing rate delivered via mechanical ventilator.
Study NCT04633343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large volume breath and slow breathing rate for 5 minutes
Description: Large volume breath and slow breathing rate delivered via mechanical ventilator.
Study NCT05406934 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: obseravation with investigation
Study NCT05205447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3410738
Description: Oral LY3410738
Study NCT05205447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Itraconazole
Study NCT05205447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Oral Carbamazepine
Study NCT05537090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for Infusion
Study NCT05537090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration
Study NCT05661526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bloodpoly board game
Description: Blood transfusion training given by Bloodpoly board game
Study NCT05661526 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text-to-speech group
Description: Blood transfusion training given by text-to-speech
Study NCT06450184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Description: 1 capsule of Pimavanserin Capsule 34mg
Study NCT06450184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUPLAZID 34 MG Oral Capsule
Description: 1 capsule of Pimavanserin Capsule 34mg
Study NCT03935997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program
Description: Our team will work with long-term care homes in the study to implement the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) which consists of the following core, evidence-informed components:~Palliative Champion Teams (to provide leadership and support implementation); Palliative Care Education (including illness trajectory pamphlets); Comfort Care Rounds with staff (for capacity building and reflection); Prognostic Tools to trigger end-of-life discussions; Palliative Care Conferences with families and residents; Bereavement Pamphlets; and Post-Bereavement Follow-Up for families, and staff.
Study NCT05119933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-15293
Description: After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons (see Section 7.1). Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.
Study NCT06355817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration
Description: Vibration Assist Device, held to the forehead
Study NCT06355817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Vibration Assist Device, held to the forehead
Study NCT06355817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tapping
Description: Tapping on the forehead
Study NCT06355817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapping
Description: Tapping on the forehead
Study NCT05190185 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA06 injection
Description: The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be treated with 1×106\~1×108 CAR-T/kg. And the subjects will be administered once.
Study NCT05882032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05483842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Consisting of the words rei meaning spirit and ki meaning universal life force, Reiki means spiritually directed life force energy. Reiki practice has an important place in modern medicine and the nursing profession because it cures many diseases resistant to known treatments, has no side effects, is easy to apply, is safe, effective and economical.~In the Reiki method, which is one of the complementary and alternative methods, energy is transferred through the hands. Its basis is based on the principle that when there is a blockage in an energy center, disease occurs and the energy transferred by touching, strengthens and heals the body's self-healing ability by opening the blockages. Reiki practitioners who have received training and initiation perform the practice by holding their hands in certain positions on the recipient's body.
Study NCT05483842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Reiki
Description: Sham means to pretend; therefore, in this study, the sham Reiki placebo provider pretended to perform a Reiki session by moving her hands on the patient's body in a specific order for a 30-minute period following strictly operationalized measures.
Study NCT05333965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (lehfilcon A lens)
Description: Daily wear for 1 month.
Study NCT05333965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (comfilcon A lens)
Description: Daily wear for 1 month.
Study NCT05599633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sago starch drink
Description: Sarawak sago starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
Study NCT05599633 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch drink
Description: Corn starch drink will be provided by CRAUN throughout the study. The starch drink will be supplied in sealed aluminium sachets. Each sachet contains 25g of study starch with cocoa flavouring.
Study NCT06431698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-made silicone device
Description: Correction of deformation using the custom-made silicone device
Study NCT06431698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: adjustable Earwell device
Description: Correction of deformation using the adjustable Earwell device
Study NCT04708821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic insert 0.4Mg
Description: Dextenza 0.4Mg Ophthalmic Insert
Study NCT04708821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.2% loteprednol etabonate ophthalmic suspension
Description: 0.2% loteprednol etabonate ophthalmic suspension
Study NCT04708821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olopatadine hydrochloride ophthalmic solution 0.7%
Description: olopatadine hydrochloride ophthalmic solution 0.7%
Study NCT04847648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-polishing
Description: Air-polishing with erythritol powder during non-surgical therapy (at baseline, 5 seconds per surface, and, if necessary, at 3 months).
Study NCT04847648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical decontamination
Description: Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
Study NCT04847648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical decontamination
Description: Mechanical instrumentation of implant surfaces during non-surgical therapy (at baseline and, if necesarry at 3 months) including the use of hand instruments and polishing cups aiming at the removal of all soft and hard deposits from the target implant.
Study NCT05153915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus granules
Description: Oral
Study NCT06534463 — intervention group
Intervention type: OTHER
Intervention: All treatment regimen selections and usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Description: The dosage and duration of any drug in this study will be determined by the physician based on local clinical practice and local drug labels. The drugs in this study include, but are not limited to, Obinutuzumab, Rituximab, Bruton tyrosine kinase inhibitors, and Lenalidomide. In this non-interventional study, all treatment drug usage will be determined by the physician based on clinical practice and/or the respective drug labels in China.
Study NCT05098600 — intervention group
Intervention type: OTHER
Intervention: Exposure of interest
Description: Common autoimmune and atopic conditions consist of atopic dermatitis, allergic rhinitis, asthma, Crohn's disease, ulcerative colitis, Celiac disease, Pernicious anaemia, Type 1 diabetes, Autoimmune thyroiditis (Hashimoto's thyroiditis, Grave's disease, atrophic, unspecified), rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polymyalgia rheumatica, Systemic lupus erythematosus, Sjogren syndrome, psoriasis, vitiligo, Multiple sclerosis
Study NCT04795427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asciminib
Description: Asciminib comes in 20 mg and 40 mg tablets and is taken orally twice daily
Study NCT04795427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: best available treatment
Description: Best available treatment will be based on investigator's choice identified prior to randomization. Dose and frequency will depend on label and institutional guidelines for various BAT
Study NCT06190951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: Administered intravenous (IV) every 3 weeks (Q3W) Phase 3 active comparator
Study NCT06190951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: Administered IV Q3W Phase 2
Study NCT06190951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cemiplimab
Description: Administered IV Q3W Phase 2 Active Comparator
Study NCT06190951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab+fianlimab
Description: Administered IV Q3W Phase 3 Either fianlimab HD or fianlimab LD in combination with cemiplimab will be chosen for Phase 3
Study NCT05375747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of remimazolam and remifentanil.
Study NCT05375747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: For induction and maintenance of anesthesia, total intravenous anesthesia is performed using continuous intravenous infusion of propofol and remifentanil.
Study NCT05550649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
Study NCT05550649 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: embolization
Description: Prophylactic arterial embolization is performed for the artery in the diseased blood supply area. The embolization material: gelatin sponge particles are recommended, and micro-steel ring can be used as an auxiliary if necessary; after operation, symptomatic and supportive treatment such as acid suppression, hemostasis, blood transfusion, and fluid replacement are given according to the condition.
Study NCT04621071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (2 strains 10x10^9 UFC)
Description: Probiotic vs Placebo (1:1)
Study NCT04621071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (potato starch and magnesium stearate)
Description: Probiotic vs Placebo (1:1)
Study NCT06297980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized modifications to treatment to address menstrual cycle effects on glycemia
Description: The study physician will examine glucose patterns measured using continuous glucose monitoring over a 3 month observational period to identify hypo- or hyperglycemia related to menstrual cycle phase or exercise, and will provide changes to insulin basal or bolus rates, carbohydrate ratios, post-exercise food intake or use of sleep mode on automated insulin delivery systems.
Study NCT05247216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 800 mg QD group
Description: daily oral administrtion of Hemay007 800 mg QD for 12 weeks, 4 tablets of 200mg Hemay007 and 2 tablets of placebo.
Study NCT05247216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 1200 mg QD group
Description: daily oral administrtion of Hemay007 1200 mg QD for 12 weeks, 6 tablets of 200mg Hemay007.
Study NCT05247216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay007 600 mg QD group
Description: daily oral administrtion of Hemay007 600 mg QD for 12 weeks, 3 tablets of 200mg Hemay007 and 3 tablets of placebo.
Study NCT05247216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay007 placebo group
Description: daily oral administrtion of placebo for 12 weeks 6 tablets of placebo.
Study NCT05250089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation
Description: Each simulation will focus on a trauma case deemed to be complex, that is to say one involving difficult decision-making. Each simulation session lasts approximately thirty minutes. It includes a time to complete the questionnaires necessary for carrying out the study, before and / or after the simulated practice depending on the type of questionnaire, a brief briefing on the simulation scenario, and the time for the simulated practice.
Study NCT05305339 — intervention group
Intervention type: OTHER
Intervention: Placental and Umbilical cord biopsy
Description: After delivery of the placenta, two tissue fragments, 1st piece about 1x1 cm from the central zone of the maternal surface of the placenta and 2nd piece about 1 x 1 cm from mid segment of umbilical cord will be cut. Each of both samples will be divided and fixed in either a 10% formalin for light microscopic examination or glutaraldehyde 2.5% for Electron microscopic examination. Paraffin-embedded placental tissue sections (4 μm thick) will be used for histological (stained with hematoxylin and eosin) and immunohistochemical examination using primary antibody markers for telocytes CD117, CD34, vimentin, SMA (smooth muscle actin), and the new telocyte marker TMEM16a (DOG-1).
Study NCT05588895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: For patients randomized to notification, the affiliated non-EP cardiologist, if present, or if patient does not have one, the PCP will be notified and will receive an electronic health record (EHR) message notifying them of the presence of CAC (with images) and the ACC/AHA guideline recommendation to consider starting statin therapy. Simultaneously, the patient will be notified via a MyHealth message describing the presence of CAC with personalized scan images, its significance, and the recommendation that statin therapy should be considered.~For the notification arm, we will check for either statin prescription or a documented discussion in the EHR at 2 months. For those not prescribed a statin and without a documented discussion in Epic at 2 months follow-up, we will send a repeat notification to their home address and to their affiliated clinician.
Study NCT05973630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATA-200
Description: single intravenous infusion
Study NCT05793437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: permissive hypercapnia
Description: Tidal volume (6-8ml/kg) and respiratory rate is adjusted to achieve the objective values of PaCO2:45～55mmHg